zovirax 800 mg dispersible tablets
pco manufacturing ltd. - aciclovir - dispersible tablet - 800 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
zovirax tablet
glaxo saudi arabia, saudi arabia - acyclovir (aciclovir) - tablet - 400 mg
zovirax tablet
glaxo saudi arabia, saudi arabia - acyclovir (aciclovir) - tablet - 800 mg
zovirax ™ 200mg
25's( 5 x 5's blister) -
zovirax tablet
glaxo saudi arabia, saudi arabia - acyclovir - tablet - 400 mg
zovirax tablet
glaxo saudi arabia, saudi arabia - acyclovir - tablet - 800 mg
zovirax 800 mg dispersible tablets
imed healthcare ltd. - aciclovir - dispersible tablet - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
zovirax 800 mg dispersible tablets
merit pharmaceuticals limited - aciclovir - dispersible tablet - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
zovirax 800 mg dispersible tablets
lexon pharmaceuticals (ireland) limited - aciclovir - dispersible tablet - nucleosides and nucleotides excl. reverse transcriptase inhibitors; aciclovir
zelitrex valaciclovir 500mg (as hydrochloride) tablet bottle
arrotex pharmaceuticals pty ltd - valaciclovir hydrochloride, quantity: 556 mg (equivalent: valaciclovir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; povidone; magnesium stearate; colloidal anhydrous silica; carnauba wax; colour - for the treatment of herpes zoster (shingles) in adult patients who commence therapy within 72 hours of the onset of rash. for the treatment of ophthalmic zoster. for the treatment of herpes labialis (cold sores). for the treatment of clinical episodes of genital herpes simplex infections. for the prevention of recurrent genital herpes. reduction of transmission of genital herpes in patients suffering from recurrent genital herpes. in addition to therapy with zelitrex, it is recommended that patients use safer sex practices. (see precautions). prophylaxis of cytomegalovirus (cmv) infection and disease following solid organ transplantation in patients at risk of cmv disease.